Methods for analyzing methylated CpG islands and GC rich regions
View Patent ↗The present invention provides CpG islands and GC rich regions and methods for identifying methylation states for these CpG islands and GC rich regions. The present invention also provides methods for identifying genes regulated by these CpG islands and GC rich regions, and provides methods for identifying a population of CpG islands and GC rich regions in a genome.
1. A method for determining the DNA methylation status of a combination of DNA sequences from a genomic DNA sample comprising determining the methylation status of a combination of DNA sequences, wherein the sequences consist of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:16, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:26, SEQ ID NO:29, and SEQ ID NO:30.
2. The method of claim 1 , wherein determining the methylation status comprises use of a methylation-sensitive restriction enzyme.
3. The method of claim 2 , wherein the methylation-sensitive restriction enzyme is one or more of SmaI, SacII, EagI, MspI, HpaII, BstUI and BssHII.
4. The method of claim 1 , wherein determining the methylation status comprises a methylation-specific polymerase chain reaction (MSP).
5. The method of claim 1 , wherein determining the methylation status comprises use of bisulfite.
6. The method of claim 1 , wherein the sample is from a subject known to have cancer.
7. The method of claim 1 , wherein the methylation status is hypomethylation.
8. The method of claim 1 , further comprising cleaving the genomic DNA with both a restriction endonuclease that cleaves at a recognition site comprising adenosine and thymidine residues and a restriction endonuclease that cleaves at an unmethylated restriction site comprising cytidine and guanosine residues.
9. The method of claim 1 , wherein determining the methylation status comprises detecting hybridization of one or more oligonucleotide probes.
10. The method of claim 9 , wherein the oligonucleotide probe is detectably labeled.
11. The method of claim 1 , wherein the genomic DNA sample is human.